Compare
AbbVie vs Arcus Biosciences (ABBV vs RCUS)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year AbbVie (ABBV) returned +34.4% and Arcus Biosciences (RCUS) -7.4%; so far this year the figures are +27.5% and -23.3%.
AbbVie is the larger company by market value, about 195.8 times the size of Arcus Biosciences.
Revenue grew +10.7% at ABBV and +20.0% at RCUS over the last year.
ABBV yields 2.38%. RCUS pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| ABBV | RCUS | |
|---|---|---|
| Price | $291.31 | $18.28 |
| 1-day | +1.07% | +3.34% |
| YTD | +27.49% | -23.29% |
| 1 year | +34.39% | -7.44% |
| 3 years | +104.47% | +15.55% |
| Market cap | $514.9B | $2.6B |
| P/E | 50.1 | — |
| P/S | 7.80 | 48.74 |
| P/B | — | 7.35 |
| Revenue growth | +10.70% | +20.00% |
| EPS growth | +340.20% | — |
| Gross margin % | 73.7 | — |
| Net margin % | 15.7 | -838.9 |
| ROE % | — | -126.5 |
| Debt / equity | — | 0.28 |
| FCF yield % | 3.7 | -17.7 |
| Dividend yield % | 2.38 | — |
| Beta | -0.03 | 1.54 |
| RSI (14) | 59.7 | 37.0 |
| Technical rating |